Наукова електронна бібліотека
періодичних видань НАН України

Перегляд Experimental Oncology, 2012, № 3 за назвою

Репозиторій DSpace/Manakin

Перегляд Experimental Oncology, 2012, № 3 за назвою

Сортувати за: Порядок: Результатів:

  • Wu, P.C.; Wang, Q.; Grobman, L.; Chu, E.; Wu, D.Y. (Experimental Oncology, 2012)
    Accelerated cellular senescence (ACS) is an emerging concept that implicates sustained, telomere-independent cell cycle arrest of neoplastic cells in response to chemotherapeutic agents, ionizing radiation, oxidative stress, ...
  • Yalcin, T.J.; Haimovitz-Friedman, A.; Verheij, M. (Experimental Oncology, 2012)
    Early response prediction is considered an essential tool to obtain a more customized anticancer treatment because it allows for the identification of patients who will benefit most from a particular therapy and prevents ...
  • Balcer-Kubiczek, E.K. (Experimental Oncology, 2012)
    Radiation therapy achieves its therapeutic effects by inducing apoptosis and non-apoptotic cell death. The aim of this focused review is to highlight the aspects of the cell death pathways most relevant to conventional ...
  • Crowder, R.N.; El-Deiry, W.S. (Experimental Oncology, 2012)
    Research on TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors has advanced tremendously over the past 17 years. Initial observations of TRAIL and TRAIL receptor-mediated tumor cell toxicity led to enthusiasm ...
  • Fiandalo, M.V.; Kyprianou, N. (Experimental Oncology, 2012)
    Emergence of castration-resistant metastatic prostate cancer is due to activation of survival pathways, including apoptosis suppression and anoikis resistance, and increased neovascularization. Thus targeting of apoptotic ...
  • Safa, A.R. (Experimental Oncology, 2012)
    Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a master anti-apoptotic regulator and resistance factor that suppresses tumor necrosis factor-α (TNF-α), Fas-L, and TNF-related apoptosis-inducing ...
  • Monian, P.; Jiang, X. (Experimental Oncology, 2012)
    In mammalian cells, the mitochondrial pathway of apoptosis plays a key role in various biological processes and has been extensively studied. One of the signature features of this pathway is permeabilization of the outer ...
  • Wlodkowic, D.; Skommer, J.; Darzynkiewicz, Z. (Experimental Oncology, 2012)
    Characteristic changes in cell morphology paralleled by the appearance of a multitude of molecular and biochemical markers occur during apoptosis. These changes vary depending on the cell type, mechanism of induction of ...
  • Chekhun, V.F. (Experimental Oncology, 2012)
  • Benbrook, D.M.; Long, A. (Experimental Oncology, 2012)
    A single cell has the potential to kill an entire human being. Efforts to cure cancer are limited by survival of individual cancer cells despite immune surveillance and toxic therapies. Understanding the intricate network ...
  • Caruso, R.A.; Fedele, F.; Finocchiaro, G.; Arena, G.; Venuti, A. (Experimental Oncology, 2012)
    The recognition and removal of apoptotic cells by tissue macrophages and nonprofessional phagocytes, in a process called efferocytosis, is critical for development, tissue homeostasis and resolution of inflammation. Apoptotic ...
  • Clarke, P.G.H.; Clarke, S. (Experimental Oncology, 2012)
    This paper reviews research on cell death in the 19th C. The first report of cell death was by Vogt in 1842, which was remarkably soon after the establishment of the cell theory by Schleiden and Schwann between 1838 and ...
  • Maghsoudi, N.; Zaketi, Z.; Lockshin, R.A. (Experimental Oncology, 2012)
    The story of cell death began with the origins of cell biology, including important observations by Elie (Ilya) Metchnikoff, who realized that phagocytes engulfed dying cells. Most of the early studies were observational. ...
  • Tirodkar, T.S.; Voelkel-Johnson, C. (Experimental Oncology, 2012)
    Forty years ago, the term “apoptosis” was introduced to describe a form of programmed cell death. Key players that mediate apoptosis at the molecular level such as caspases, death receptors, Bcl-2 family members have since ...
  • Miura, K.; Fujibuchi, W.; Unno, M. (Experimental Oncology, 2012)
    Elimination of superfluous or mutated somatic cells is provided by various mechanisms including apoptosis, and deregulation of apoptotic signaling pathways contributes to oncogenesis. 40 years have passed since the term ...
  • Weyhenmeyer, B.; Murphy, A.C.; Prehn, J.H.M.; Murphy, B.M. (Experimental Oncology, 2012)
    Most cells express a variety of both anti-apoptotic and pro-apoptotic Bcl-2 proteins and the interaction within this family dictates whether a cell survives or dies. The dysregulation of the anti-anti-apoptotic Bcl-2 family ...
  • Demchenko, A.P. (Experimental Oncology, 2012)
    The strong plasma membrane asymmetry existing in living cells is lost on apoptosis, and it is commonly detected with the probes interacting strongly and specifically with phosphatidylserine (PS). This phospholipid becomes ...
  • de Almagro, M.C.; Vucic, D. (Experimental Oncology, 2012)
    Cell death regulation is vital for maintenance of homeostasis and proper development of multicellular organisms. Inhibitor of apoptosis (IAP) proteins are implicated in multiple ways in cell death regulation, ranging from ...
  • Nowsheen, S.; Yang, E.S. (Experimental Oncology, 2012)
    Apoptosis is a finely regulated process that serves to determine the fate of cells in response to various stresses. One such stress is DNA damage, which not only can signal repair processes but is also intimately involved ...
  • Yurchenko, M.; Shlapatska, L.M.; Sidorenko, S.P. (Experimental Oncology, 2012)
    CD95, also called Fas or APO-1, was the first death receptor (DR) identified and characterized. Studies on CD95 receptor signaling revealed the versatile principles of cell fate regulation via DR. DRs could exert both pro- ...

Пошук


Розширений пошук

Перегляд

Мій обліковий запис